用于治疗过敏性鼻炎、慢性鼻-鼻窦炎和鼻息肉的生物制剂。
Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
机构信息
Department of Medicine, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
Department of Medicine, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA; Department of Microbiology, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
出版信息
Immunol Allergy Clin North Am. 2020 Nov;40(4):539-547. doi: 10.1016/j.iac.2020.06.001. Epub 2020 Sep 9.
Abstract
Allergic rhinitis (AR), most presentations of nasal polyposis (NP), and many presentations of chronic rhinosinusitis are type 2 disorders characterized by expression of interleukin (IL)-4, IL-5, and IL-13. Neutralization of IgE with anti-IgE (omalizumab) has proven efficacy in AR. Similarly, in addition to anti-IgE, blockade of IL-5/IL-5 (mepolizumab, reslizumab, benralizumab) and dual blockade of IL-4 and IL-13 with anti-IL-4R (dupilumab) have demonstrated efficacy in NP. However, these agents are expensive and future studies are essential to evaluate cost effectiveness in comparison with current medical and surgical therapies. This article reviews biologics as potential interventions in AR, chronic rhinosinusitis, and NP.
摘要
变应性鼻炎（AR）、大多数鼻息肉（NP）表现形式和许多慢性鼻-鼻窦炎表现形式均为 2 型疾病，其特征是白细胞介素（IL）-4、IL-5 和 IL-13 的表达。抗 IgE（奥马珠单抗）中和 IgE 已被证明对 AR 有效。同样，除了抗 IgE 外，阻断 IL-5/IL-5（美泊利单抗、瑞利珠单抗、贝那利珠单抗）和双重阻断 IL-4 和 IL-13 的抗 IL-4R（度普利尤单抗）已被证明对 NP 有效。然而，这些药物价格昂贵，未来的研究对于评估其与当前的药物和手术治疗相比的成本效益至关重要。本文综述了生物制剂作为 AR、慢性鼻-鼻窦炎和 NP 的潜在干预措施。
相似文献
1
Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Immunol Allergy Clin North Am. 2020 Nov;40(4):539-547. doi: 10.1016/j.iac.2020.06.001. Epub 2020 Sep 9.
2
Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Curr Allergy Asthma Rep. 2021 Jun 10;21(6):36. doi: 10.1007/s11882-021-01013-y.
3
The Role of Biologics in the Treatment of Nasal Polyps.
Immunol Allergy Clin North Am. 2020 May;40(2):295-302. doi: 10.1016/j.iac.2019.12.006. Epub 2020 Jan 8.
4
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Expert Rev Clin Immunol. 2020 Dec;16(12):1115-1125. doi: 10.1080/1744666X.2021.1847083. Epub 2020 Nov 15.
5
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420950851. doi: 10.1177/2058738420950851.
6
The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.
Int Forum Allergy Rhinol. 2024 Jul;14(7):1261-1265. doi: 10.1002/alr.23344. Epub 2024 Mar 11.
7
Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis.
Laryngoscope. 2000 Jun;110(6):1056-62. doi: 10.1097/00005537-200006000-00031.
8
Biologics in Chronic Rhinosinusitis: Current and Emerging.
Immunol Allergy Clin North Am. 2024 Nov;44(4):657-671. doi: 10.1016/j.iac.2024.07.005. Epub 2024 Aug 17.
9
Biologics for chronic rhinosinusitis with nasal polyps.
J Allergy Clin Immunol. 2020 Mar;145(3):725-739. doi: 10.1016/j.jaci.2020.01.020.
10
Monoclonal Antibodies for the Treatment of Nasal Polyps.
Immunol Allergy Clin North Am. 2017 May;37(2):357-367. doi: 10.1016/j.iac.2017.01.008. Epub 2017 Mar 2.
引用本文的文献
1
Interleukin 8 Molecular Interplay in Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyps: A Scoping Review.
Life (Basel). 2025 Mar 15;15(3):469. doi: 10.3390/life15030469.
2
Correlation between monocyte and length of in-hospital stay in patients with allergic rhinitis: data from the MIMIC-IV database.
BMC Anesthesiol. 2025 Mar 4;25(1):113. doi: 10.1186/s12871-025-02979-2.
3
Insufficiency of Laboratory Data in Reflecting Allergic Rhinitis Severity Based on the Allergic Rhinitis and Its Impact on Asthma Guideline in Korean Patients.
J Rhinol. 2024 Mar;31(1):17-21. doi: 10.18787/jr.2023.00066. Epub 2024 Mar 31.
4
The sinus surgery completeness score: a radiological assessment of the extent of endoscopic sinus surgery.
Eur Arch Otorhinolaryngol. 2025 Mar;282(3):1301-1309. doi: 10.1007/s00405-024-09110-0. Epub 2024 Dec 4.
5
V Brazilian Consensus on Rhinitis - 2024.
Braz J Otorhinolaryngol. 2025 Jan-Feb;91(1):101500. doi: 10.1016/j.bjorl.2024.101500. Epub 2024 Sep 7.
6
Blood and local eosinophil levels in chronic rhinitis: Observations during seasonal allergen exposure and non-exposure.
World Allergy Organ J. 2024 Jul 4;17(7):100930. doi: 10.1016/j.waojou.2024.100930. eCollection 2024 Jul.
7
Efficacy, Safety, and Continuation of Biological Therapy in Older Patients with Asthma in a Real-World Setting: A Retrospective Observational Study.
Yonago Acta Med. 2024 Apr 22;67(2):114-123. doi: 10.33160/yam.2024.05.003. eCollection 2024 May.
8
Efficacy and Safety of Monoclonal Antibodies for the Treatment of Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Dig Dis Sci. 2024 Jul;69(7):2530-2539. doi: 10.1007/s10620-024-08413-w. Epub 2024 May 6.
9
A Review on Novel Therapeutic Modalities and Evidence-based Drug Treatments against Allergic Rhinitis.
Curr Pharm Des. 2024;30(12):887-901. doi: 10.2174/0113816128295952240306072100.
10
Recent advances in mass spectrometry-based proteomics and metabolomics in chronic rhinosinusitis with nasal polyps.
Front Immunol. 2023 Sep 6;14:1267194. doi: 10.3389/fimmu.2023.1267194. eCollection 2023.
本文引用的文献
1
Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Am J Rhinol Allergy. 2020 Mar;34(2):196-208. doi: 10.1177/1945892419884774. Epub 2019 Nov 1.
2
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
3
Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2812-2820.e3. doi: 10.1016/j.jaip.2019.05.009. Epub 2019 May 22.
4
Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis.
J Allergy Clin Immunol. 2019 Mar;143(3):1163-1175.e15. doi: 10.1016/j.jaci.2018.07.006. Epub 2018 Jul 25.
5
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.
6
Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.
Rhinology. 2018 Mar 1;56(1):42-45. doi: 10.4193/Rhino17.139.
7
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14. doi: 10.1016/j.jaci.2017.05.044. Epub 2017 Jul 4.
8
Distribution, subtype population, and IgE positivity of mast cells in chronic rhinosinusitis with nasal polyps.
Ann Allergy Asthma Immunol. 2017 Aug;119(2):120-128. doi: 10.1016/j.anai.2017.05.019. Epub 2017 Jun 19.
9
Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps.
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1582-1588.e3. doi: 10.1016/j.jaip.2017.04.009. Epub 2017 May 10.
10
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Lancet Respir Med. 2017 May;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. Epub 2017 Apr 5.
Zotero 插件